GRAIL to start REACH study of Galleri multi-cancer early detection test
The trial is intended to assess and compare the group of Medicare beneficiaries who undergo standard care along…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
21 Nov 23
The trial is intended to assess and compare the group of Medicare beneficiaries who undergo standard care along…
21 Nov 23
UDX’ Signal-C is designed to detect methylation DNA patterns and fragments released by circulating colorectal cancer tumours in…
15 Nov 23
The next-generation screening test of Geneoscopy is a multi-target stool RNA biomarker panel, designed to identify colorectal cancer…
15 Nov 23
Both companies will work together to integrate and improve a diagnostic system to be used in clinical environments…
10 Nov 23
The EsoGuard Esophageal DNA test is intended to help in preventing cancer and associated death through early detection…
06 Nov 23
Under the partnership, affiliates of Solaris Health will use Velsera’s Clinical Genomics Workspace platform to provide inherited cancer…
01 Nov 23
GMED, a French Notified Body specialising in medical device assessments, issued the certification contract authorising the use of…
25 Oct 23
The LucentAD p-Tau 217 test leverages a combination of Quanterix’ Simoa technology and J&J Innovative Medicine’s p-Tau 217…
18 Oct 23
The Philadelphia-based FloBio has designed the precision, point-of-care test Direct Oral Anticoagulant detection test to aid emergency medical…
17 Oct 23
The Aptiva CTD Essential reagent can generate a throughput of up to 600 results per hour to streamline…